Dividend Portfolio member Merck continues Keytruda momentum
Merck's cancer drug Keytruda continues to build global momentum. Today Merck (MRK) announced that China has approved Keytruda for first-line treatment of metastatic nonsquamous non-small cell lung cancer in combination with chemotherapy. The stock, which is a member...
Government action on drug prices seems far, far away
The format was familiar: Seven CEOs sit in front of a Senate Committee probing their industry's business practices. But whereas a Congressional hearing a decade ago marked a key moment in what was a costly public reckoning for the tobacco industry, today's hearing...Drug stocks get de-risked after Trump’s plan shows no teeth
President Donald Trump speech last week on drug prices, what he billed as “the most sweeping action in history to lower the price of prescription drugs for the American people,” didn’t deliver any of the ghosts and goblins that drug makers feared. Drug stocks by and large climbed on the proposals. Which turns stocks in the drug sector into one of the most interesting places to stash money for the next six months for investors looking for decent upside and above average safety.
Merck moves lower in spite of earnings beat
This morning before the New York markets opened Merck (MRK) reported earnings of $1.05 a share, ahead of the $1.00 a share forecast by Wall Street analysts. Earnings were up 19.3% from the first quarter of 2017. Revenue grew 6% to $10 billion. That narrowly missed the...
Adding Merck to my Dividend Portfolio
News out of the imuno-oncology sector of the biotech world has hit stocks in my portfolios such as Incyte (INCY) and Nektar Therapeutics (NKTR) hard. But, I'd argue that it has left Keytruda and its owner Merck (MRK) in a measurably stronger position in the market for...
Saturday Night Quarterback says, For the week ahead expect…
So much news. And so much that has the potential to move the financial markets. Let’s start on the economic side, ok? Monday we get reports on personal income and inflation. And on the earnings side? Lots and lots of reports that could change the tone of this market. The biggest are Microsoft, (MSFT), PayPal (PYPL) and Facebook (FB) on Wednesday January 31 and then Alphabet (GOOG), Apple (AAPL) and Amazon (AMZN) on Thursday, February 1.
Notes You Need for January 17: China data, casino REITs, natural gas, target price increase for homebuilders, Bitcoin, MRK, U.S. dollar,
In my daily trawling through the market I come upon lots of tidbits of knowledge that I think are important to investors but that don’t justify a full post. I’ve decided to start compiling these notes here each day in a kind of running mini blog that I’m calling Notes You Need. A typical items resembles this from today: “4:20 p.m.: The U.S. Dollar Index gave up a morning gain to fall back to 90.32 before rallying again to close at 90.736, up 0.34 on the day. Some analysts think that the 90 level on the index might give support to the U.S. currency against other major currencies. Others think the dollar is on the verge of falling to a new thee-year low that could open the way to further declines.”
Merck writes off $2.9 billion it spent on hepatitis C drug purchased in 2014; here’s who to watch in the biotech sector after this news
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...Saturday Night Quarterback says (on a Sunday), For the week ahead expect…
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...So much for the Trump victory drug rally
“I’m going to bring down drug prices. I don’t like what’s happened with drug prices,” President-elect Donald Trump said in an interview with Time posted on the magazine’s website this morning. So much, the stock market has concluded today, for the idea that a President Trump would be friendlier than a President Clinton to the drug industry.
It’s not just Pfizer–all of Big Pharma is looking to restructure and why that’s good for biotech
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...Download Jim’s eBook for Free
